Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
76 hedge funds and large institutions have $209M invested in Syros Pharmaceuticals, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 31 increasing their positions, 10 reducing their positions, and 7 closing their positions.
271% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 7
210% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 10
33% more funds holding
Funds holding: 57 → 76 (+19)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less capital invested
Capital invested by funds: $240M → $209M (-$31.6M)
46% less call options, than puts
Call options by funds: $147K | Put options by funds: $270K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.1M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$3.65M |
| 3 |
Millennium Management
New York
|
+$2.62M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.34M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.4M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$961K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$863K |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$260K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$171K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MAM
76
Meeder Asset Management
Dublin,
Ohio
| $1.21K | -$248 | -2 | -14% |
|
|
77
Wellington Management Group
Boston,
Massachusetts
| – | -$13.4M | -103,086 | Closed |
|
|
OM
78
Opaleye Management
Boston,
Massachusetts
| – | -$961K | -7,407 | Closed |
|
79
Marshall Wace
London,
United Kingdom
| – | -$170K | -1,310 | Closed |
|
80
Balyasny Asset Management
Chicago,
Illinois
| – | -$134K | -1,030 | Closed |
|
81
Citigroup
New York
| – | -$25K | -193 | Closed |
|
|
DOA
82
D'Orazio & Associates
Falls Church,
Virginia
| – | -$1K | -10 | Closed |
|
SYRS Hedge Fund Activity: Q2 2018 in Review
76 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2018, worth a combined $209M — down 13% from $240M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new SYRS positions and 7 closed out — a net gain of 19 holders — while 31 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $8.1M. The largest seller was Wellington Management Group, exiting entirely with an estimated $13.4M sold.
- 76 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2018, up from 57 in Q1 2018.
- Funds reported $209M of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2018, down 13% quarter-over-quarter.
- 26 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2018 and 7 closed out, a net change of +19 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q2 2018 was BlackRock, an estimated $8.1M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q2 2018 was Wellington Management Group, an estimated $13.4M sold.
Based on aggregated 13F filings for Q2 2018.